WallStreetZenWallStreetZen

NASDAQ: KLRA
Kailera Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for KLRA

Based on 3 analysts offering 12 month price targets for Kailera Therapeutics Inc

Min Forecast
$30.00+68.63%
Avg Forecast
$38.00+113.6%
Max Forecast
$48.00+169.81%

Should I buy or sell KLRA stock?

Based on 3 analysts offering ratings for Kailera Therapeutics Inc.

Strong Buy
Strong Buy
2 analysts 66.67%
Buy
1 analysts 33.33%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although KLRA's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates KLRA as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -6.47% per year. Learn More

Be the first to know when Wall Street analysts revise their KLRA stock forecasts and price targets.

KLRA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-05-12
lockedlocked$00.00+00.00%2026-05-12
lockedlocked$00.00+00.00%2026-05-12

1 of 1

Forecast return on equity

Is KLRA forecast to generate an efficient return?

Insufficient data to display

Forecast return on assets

Is KLRA forecast to generate an efficient return on assets?

Company
N/A
Industry
27.38%

KLRA earnings per share forecast

What is KLRA's earnings per share in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
-$3.09
Avg 2 year Forecast
-$4.23
Avg 3 year Forecast
-$3.83

KLRA revenue forecast

What is KLRA's revenue in the next 3 years based on estimates from 6 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

KLRA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
KLRA$17.79$38.00+113.60%Strong Buy
ZLAB$20.50$37.67+83.74%Strong Buy
IOVA$5.17$8.50+64.41%Strong Buy
COAG$49.23$45.40-7.78%Strong Buy
NUVB$6.55$13.40+104.58%Buy
View Top Biotech Stocks

Kailera Therapeutics Stock Forecast FAQ

Is Kailera Therapeutics Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: KLRA) stock is to Strong Buy KLRA stock.

Out of 3 analysts, 2 (66.67%) are recommending KLRA as a Strong Buy, 1 (33.33%) are recommending KLRA as a Buy, 0 (0%) are recommending KLRA as a Hold, 0 (0%) are recommending KLRA as a Sell, and 0 (0%) are recommending KLRA as a Strong Sell.

If you're new to stock investing, here's how to buy Kailera Therapeutics stock.

What is KLRA's earnings growth forecast for 2026-2028?

(NASDAQ: KLRA) Kailera Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.57%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.44%.

Kailera Therapeutics's earnings in 2026 is N/A.On average, 6 Wall Street analysts forecast KLRA's earnings for 2026 to be -$400,435,468, with the lowest KLRA earnings forecast at -$393,620,317, and the highest KLRA earnings forecast at -$402,689,910. On average, 6 Wall Street analysts forecast KLRA's earnings for 2027 to be -$548,451,219, with the lowest KLRA earnings forecast at -$613,285,849, and the highest KLRA earnings forecast at -$406,771,226.

In 2028, KLRA is forecast to generate -$495,588,451 in earnings, with the lowest earnings forecast at -$651,378,138 and the highest earnings forecast at -$263,925,143.

What is KLRA's revenue growth forecast for 2026-2028?

(NASDAQ: KLRA) Kailera Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.68%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.13%.

Kailera Therapeutics's revenue in 2026 is N/A.On average, 6 Wall Street analysts forecast KLRA's revenue for 2026 to be $0, with the lowest KLRA revenue forecast at $0, and the highest KLRA revenue forecast at $0. On average, 6 Wall Street analysts forecast KLRA's revenue for 2027 to be $0, with the lowest KLRA revenue forecast at $0, and the highest KLRA revenue forecast at $0.

In 2028, KLRA is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is KLRA's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: KLRA) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 27.38%.

What is KLRA's Price Target?

According to 3 Wall Street analysts that have issued a 1 year KLRA price target, the average KLRA price target is $38.00, with the highest KLRA stock price forecast at $48.00 and the lowest KLRA stock price forecast at $30.00.

On average, Wall Street analysts predict that Kailera Therapeutics's share price could reach $38.00 by May 12, 2027. The average Kailera Therapeutics stock price prediction forecasts a potential upside of 113.6% from the current KLRA share price of $17.79.

What is KLRA's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: KLRA) Kailera Therapeutics's current Earnings Per Share (EPS) is N/A. On average, analysts forecast that KLRA's EPS will be -$3.09 for 2026, with the lowest EPS forecast at -$3.04, and the highest EPS forecast at -$3.11. On average, analysts forecast that KLRA's EPS will be -$4.23 for 2027, with the lowest EPS forecast at -$4.73, and the highest EPS forecast at -$3.14. In 2028, KLRA's EPS is forecast to hit -$3.83 (min: -$5.03, max: -$2.04).

What is KLRA's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: KLRA) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.